CytoDyn's PRO 140 meets in Phase IIb/III for HIV infection

CytoDyn Inc. (OTCBB:CYDY) reported data from the double-blind, U.S. Phase IIb/III CD02 trial in 52 patients with HIV infection who were failing their current HIV therapy showing that a 350 mg subcutaneous injection of PRO 140 plus antiretroviral therapy (ART) met the primary endpoint of a greater proportion of patients with a ≥0.5 log₁₀ reduction in HIV-1 RNA viral load from baseline to week one vs. placebo plus ART (p<0.01).

Following the one-week period, all patients are continuing in the trial to receive once-weekly PRO 140 plus ART for an additional 24 weeks...